Download by
Scanning QR Code
No Stock Yet
Ascletis Pharma Eyes KPMG as New Auditor
Ernst & Young will retire as Ascletis Pharma's (HKG:1672) auditor after the parties failed to reach a consensus on the proposed audit fee for the year 2023. The drugmaker is looking to hire KPMG as it
Geli Pharmaceutical-B (01672) intends to appoint KPMG as the new auditor
According to the Zhitong Finance App, Geli Pharmaceutical-B (01672) announced that since the company failed to reach an agreement with Ernst & Young on the proposed audit fee for the year ending December 31, 2023, Ernst & Young will not renew the company's auditor. Therefore, Ernst & Young will not seek re-election as the company's auditor at the company's annual shareholders' meeting to be held on June 29, 2023. Ernst & Young will retire as corporate auditor at the current Annual General Meeting of Shareholders at the end of its current term of office. According to the recommendations of the company's audit committee, the board of directors has decided to recommend the committee
Ascletis Pharma Proposes Up to HK$200 Million Share Repurchase; Shares Climb 5%
The board of Ascletis Pharma (HKG:1672) is proposing to buy back shares of up to HK$200 million on the open market under a repurchase mandate, according to a filing on Monday. The repurchase could enh
China Green Lights Ascletis Pharma's Phase II-a Trial of Respiratory Infection Drug
The National Medical Products Administration of China has approved Ascletis Pharma's (HKG:1672) phase II-a clinical trial for its ASC10 drug to treat respiratory syncytial virus (RSV) infection.
Geli Pharmaceutical-B (01672.HK): The National Drug Administration approved ASC10 for the treatment of respiratory syncytial virus infection phase IIa clinical trial
Glonghui, May 8 丨Geli Pharmaceutical-B (01672.HK) announced that China's National Drug Administration (“China Drug Administration”) has approved the launch of a phase IIa clinical trial of ASC10 for the treatment of respiratory syncytial virus (RSV) infection. Based on available data, a randomized, double-blind, placebo-controlled phase IIa study with ASC10 was selected at a dose of 800 mg twice daily to evaluate the antiviral activity, safety, tolerability, and pharmacokinetics of ASC10 tablets in patients with mild and moderate respiratory syncytial virus infections. Gere received US food and medicine in January 2023
Geli Pharmaceutical-B (1672.HK): Excellent clinical data on ASC40 treatment of acne stage II, broad market space
Incident: The company announced that the first-of-its-kind clinical trial of ASC40 (Denifanstat), an oral fatty acid synthase (FASN) inhibitor ASC40 (Denifanstat) once a day, for treatment of acne reached the primary and critical secondary endpoints. Review opinion: Excellent clinical efficacy and good safety: ASC40 is an oral, selective small molecule FASN inhibitor. The mechanism of ASC40 in treating acne is: (1) directly inhibits facial sebum production by inhibiting fatty acid synthesis (DNL) in human sebaceous cells; and (2) by reducing cytokine secretion and Th
Ascletis Pharma Says Phase II Trial of Acne Drug Reaches Primary, Key Secondary Endpoints
08:01 AM EDT, 05/02/2023 (MT Newswires) -- Ascletis Pharma (HKG:1672) achieved primary and key secondary endpoints during the phase II clinical trial of Denifanstat, an oral fatty acid synthase (FASN)
Geli Pharmaceutical-B (01672.HK) announced that the first-of-its-kind, once-a-day, oral fatty acid synthase inhibitor ASC40 for acne phase II clinical trial has reached its end
Glonghui, May 2 | Geli Pharmaceutical-B (01672.HK) announced that the first-of-its-kind, once-a-day, oral fatty acid synthase (FASN) inhibitor ASC40 (Denifanstat) for acne phase II clinical trial has reached the main and critical secondary end points. ASC40 is an oral, selective small molecule FASN inhibitor. The mechanism of ASC40 in treating acne is: (1) directly inhibits facial sebum production by inhibiting fatty acid synthesis (DNL) of human sebaceous cells from scratch; and (2) inhibits inflammation by reducing cytokine secretion and Th17 differentiation. Should
Gelai Pharmaceutical-B: Annual Report 2022
A quick look at the Hong Kong market | The Hong Kong Index fell nearly 3% to 4,100 points; Science Network stocks weakened, Meituan fell more than 6%, and Ali rushed back down and closed down slightly
Biotech concept stocks went against the market, with Genting Xin surging more than 9%, Haohai Biotech up 6%, Tiger Pharmaceuticals up nearly 4%, Kangfang Biotech up more than 2%, and Geli Pharmaceuticals up more than 1%; semiconductor stocks weakened, Hongguang Semiconductor fell more than 14%, Shanghai Fudan fell nearly 5%, Huahong Semiconductor and Jingmen Semiconductor fell about 2%, and SMIC fell more than 1%.
Loading...
No Stock Yet